Home 
Contact Medical Affairs
Blood EOS Calculator
Vaccine Stability Calculator
REPORT SUSPECTED ADVERSE REACTIONS 
Pipeline
At GSK, our pipeline is focused on unlocking the science of the immune system, human genetics, and advanced technologies to develop vaccines and specialty medicines.
Our products in development progress through three stages: phase I, phase II, and phase III/registrational. Each of these phases allows us to assess the safety and efficacy of our investigational products to eventually provide data to support applications for regulatory approval.
DISEASE STATES
Anti-TSLP (GSK5784283)
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
Long-acting IL-5 antagonist (depemokimab)
NIMBLE: A Study of Depemokimab Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
An Open-Label Extension Study of Depemokimab in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
ICS/LAMA/LABA (fluticasone furoate/umeclidinium/vilanterol)
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
Long-acting IL-5 antagonist (depemokimab)
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
Anti-IL33 (GSK3862995B)
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
Anti-IL33 (GSK3862995B)
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
Long-acting IL-5 antagonist (depemokimab)
Endura-1: Depemokimab as an Extended treatment Duration Biologic in Adults With COPD and Type 2 Inflammation
Endura-2: Depemokimab as an Extended treatment Duration Biologic in Adults With COPD and Type 2 Inflammation
Vigilant: Evaluating the Efficacy and Safety of Initiating DepemokImab Early Therapy in COPD With Type 2 Inflammation
Anti-BLyS (belimumab)
BEconneCTD-ILD: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Long-acting IL-5 antagonist (depemokimab)
OCEAN: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory EGPA
IL-5 antagonist
SPHERE: Study in Pediatrics With HypEREosinophilic Syndrome
Long-acting IL-5 antagonist (depemokimab)
DESTINY: Depemokimab in Participants With HES, Efficacy, and Safety Trial
Anti-IL33 (GSK3862995B)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry
P2X3 Antagonist (camlipixant [BLU-5937])
CALM-1: A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults with Refractory Chronic Cough
P2X3 Antagonist (camlipixant [BLU-5937])
CALM-2: A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults with Refractory Chronic Cough
Anti-BLyS (belimumab)
BLISSc-ILD: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Anti-BLyS (belimumab)
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
0 results - Use filter to search Pipeline
Disclaimer
This document contains information for healthcare providers and is intended solely for educational purposes. This display includes ongoing clinical trials for both approved and investigational compounds.
Some agents are approved in select indications. Inclusion in this display does not imply regulatory approval for these compounds or all indications. Information about all trials can be found at www.clinicaltrials.gov.